Clinical Trials Browser

Phase 1/2 × Melphalan × 90 days × Clear all

NCT02797470 2026-05-18

Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant

Plasmablastic Lymphoma, Burkitt Lymphoma, Hodgkin Disease, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, HIV Infections, Lymphoma, T-Cell, Lymphoma, Mantle-Cell

NCT06158828 2026-05-05

ABCD-NK

Phase 1/2 Recruiting

68 enrolled

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT05436418 2026-04-27

The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation

Phase 1/2 Recruiting

260 enrolled

Other hematologic neoplasm

Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT03192397 2026-04-14

Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant

Phase 1/2 Active not recruiting

35 enrolled 19 charts

Classical hematologyLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Aplastic, Graft vs Host Disease, Hodgkin Disease, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Neoplasm, Residual

NCT01054196 2026-04-08

Lenalidomide Plus Melphalan as a Preparative Regimen for Autologous Stem Cell Transplantation in Relapsed Multiple Myeloma: A Phase 1 / 2 Study

Phase 1/2 Active not recruiting

52 enrolled 15 charts

Plasma cell

Multiple Myeloma